

# Iran Pharmaceuticals and Healthcare Report Q2 2016

<https://marketpublishers.com/r/I318C2C3640EN.html>

Date: April 2016

Pages: 92

Price: US\$ 1,295.00 (Single User License)

ID: I318C2C3640EN

## Abstracts

Includes 3 FREE quarterly updates

**BMI View:** With sanctions lifted, Iran has improving prospects of opening up to a wider diversity of trading partners and providing strategic opportunities for multinational pharmaceutical companies. By reintegrating into the financial transaction system SWIFT, the import of pharmaceutical-related products will ease and prevent future drug shortages. Both innovative and generic drugmakers will look to gain a local presence within the country, given the growing demand for essential medicines and likely improvements to healthcare provision.

### Headline Expenditure Projections

Pharmaceuticals: IRR69.55tn (USD1.93bn) in 2015 to IRR78.95trn (USD1.97bn) in 2016; +13.5% in local currency terms and -2.2% in US dollar terms. Forecast upgraded from previous quarter.

Healthcare: IRR810.99trn (USD22.53bn) in 2015 to IRR923.35trn (USD23.08bn) in 2016; +13.9% in local currency terms and +2.5% in US dollar terms. Forecast upgraded from previous quarter.

## Contents

BMI Industry View

SWOT

Industry Forecast

Pharmaceutical Market Forecast

Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2012-2020)

Healthcare Market Forecast

Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020)

Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020)

Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020)

Prescription Drug Market Forecast

Patented Drug Market Forecast

Generic Drug Market Forecast

OTC Market Forecast

Pharmaceutical Trade Forecast

Table: Pharmaceutical Trade Data And Forecasts (Iran 2014-2020)

Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2014-2020)

Industry Risk/Reward Index

Middle East and Africa Risk/Reward Index - Q2 2016

Iran Risk/Reward Index

Rewards

Risks

Regulatory Review

Intellectual Property Regime

Pricing & Reimbursement Regime

Market Overview

Healthcare Sector

Table: Healthcare Resources (Iran 2010-2015)

Table: Healthcare Personnel (Iran 2010-2015)

Table: Healthcare Activity (Iran 2010-2015)

Research & Development

Clinical Trials

Epidemiology

Competitive Landscape

Research-Based Industry

Table: Multinational Company Activity

## Generic Drugmakers

Table: Leading Drug Manufacturers, Iran - To March 2009

## Pharmaceutical Distribution

Table: Leading Distributors, Iranian Year To March 20 2008

## Pharmaceutical Retail Sector

Table: Tehran Stock Exchange - Listed Pharmaceutical Companies As Of November 2015

## Company Profile

Caspian Tamin Pharmaceutical Company

Darou Pakhsh

Exir Pharmaceuticals

Pars Darou

Zahravi Pharmaceutical Company

## Demographic Forecast

Table: Population Headline Indicators (Iran 1990-2025)

Table: Key Population Ratios (Iran 1990-2025)

Table: Urban/Rural Population & Life Expectancy (Iran 1990-2025)

Table: Population By Age Group (Iran 1990-2025)

Table: Population By Age Group % (Iran 1990-2025)

## Glossary

## Methodology

Pharmaceutical Expenditure Forecast Model

Healthcare Expenditure Forecast Model

Notes On Methodology

Risk/Reward Index Methodology

## Index Overview

Table: Pharmaceutical Risk/Reward Index Indicators

Indicator Weightings

## I would like to order

Product name: Iran Pharmaceuticals and Healthcare Report Q2 2016

Product link: <https://marketpublishers.com/r/I318C2C3640EN.html>

Price: US\$ 1,295.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I318C2C3640EN.html>